Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process
Summary
Seer announced that its special committee finished reviewing unsolicited acquisition proposals and rejected both bids. The board concluded that selling the company would undervalue Seer and its future prospects. Seer said it will continue as an independent public company and focus on demand for its proteomics platform. The company highlighted its Proteograph product suite and its position in deep, unbiased proteomics.
AskAI Classifications
Sectors
Life Sciences and Pharmaceutical
Life Sciences Management
Functions
Business Intelligence and Analytics
BI Analytics
Linked Companies
Seer
$10M to $25M